From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
α-CGRP(human) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) is a potent vasodilator .
β-CGRP (mouse) is a calcitoningene-relatedpeptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research .
CalcitoninGene RelatedPeptide (CGRP) II, rat TFA, a CGRP receptor activator, is a potent and long-lasting vasodilator. CalcitoninGene RelatedPeptide (CGRP) II TFA can be used in the research of cardiovascular diseases .
α-CGRP(human) TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) TFA is a potent vasodilator .
[Tyr22] CalcitoninGene RelatedPeptide, (22-37), rat is a fragments 22-37 of rat calcitoningene relatedpeptide (CGRP), targeting CGRP receptor and adenylate cyclase. Calcitonin is mainly produced by thyroid C cells while CGRP is secreted and stored in the nervous system .
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitoningene-relatedpeptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
CalcitoninGene RelatedPeptide (CGRP) II, rat, a CGRP receptor activator, is a potent and long-lasting vasodilator. CalcitoninGene RelatedPeptide (CGRP) II can be used in the research of cardiovascular diseases .
CGRP antagonist 4 is an antagonist of calcitoningene-relatedpeptide (CGRP) receptor. CGRP antagonist 4 shows the highest affinity for CGRP receptors in the human brain. CGRP antagonist 4 can be used to study the binding properties of non-peptidecalcitoningene-relatedpeptide (CGRP) receptor antagonist (gepants) in rat, pig and human menes .
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitoningene–relatedpeptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
Atogepant (MK-8031) is an orally active and selective calcitoningene–relatedpeptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine .
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitoningene-relatedpeptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
Rimegepant (BMS-927711) is a highly potent, oral calcitoningene-relatedpeptide (CGRP) receptor antagonist with a Ki of 0.027 nM and an IC50 of 0.14 nM for hCGRP receptor .
Telcagepant (MK-0974) is an orally active calcitoningene-relatedpeptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitoningene-relatedpeptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP .
Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the calcitoningene-relatedpeptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP .
Vazegepant (Zavegepant) is an orally activecalcitoningene-relatedpeptideCGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology .
Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitoningene-relatedpeptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
(3R,5R,6S)-Atogepant ((3R,5R,6S)-MK-8031) is the enantiomer of Atogepant (HY-109022). Atogepant is a calcitoningene-relatedpeptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine.
Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitoningene-relatedpeptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitoningenerelatedpeptide (CGRP) receptor in the hindlimb vascular bed of the cat .
α-CGRP (mouse, rat), a neuropeptide (calcitoningene-relatedpeptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
Ubrogepant-d5 (MK-1602-d5) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitoningene-relatedpeptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitoningene-relatedpeptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitoningenerelatedpeptide(CGRP) receptor in the hindlimb vascular bed of the cat .
α-CGRP(human) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) is a potent vasodilator .
Calcitoningene-relatedpeptide (CGRP) free acid is a neuropeptide. Calcitoningene-relatedpeptide can be used for the research of nociception, ingestive behaviour and modulation of the endocrine systems .
β-CGRP (mouse) is a calcitoningene-relatedpeptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research .
CalcitoninGene RelatedPeptide (CGRP) II, rat TFA, a CGRP receptor activator, is a potent and long-lasting vasodilator. CalcitoninGene RelatedPeptide (CGRP) II TFA can be used in the research of cardiovascular diseases .
α-CGRP(human) TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) TFA is a potent vasodilator .
[Tyr22] CalcitoninGene RelatedPeptide, (22-37), rat is a fragments 22-37 of rat calcitoningene relatedpeptide (CGRP), targeting CGRP receptor and adenylate cyclase. Calcitonin is mainly produced by thyroid C cells while CGRP is secreted and stored in the nervous system .
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitoningenerelatedpeptide (CGRP) receptor in the hindlimb vascular bed of the cat .
α-CGRP (mouse, rat), a neuropeptide (calcitoningene-relatedpeptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
CalcitoninGene RelatedPeptide (CGRP) II, rat, a CGRP receptor activator, is a potent and long-lasting vasodilator. CalcitoninGene RelatedPeptide (CGRP) II can be used in the research of cardiovascular diseases .
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitoningene-relatedpeptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitoningenerelatedpeptide(CGRP) receptor in the hindlimb vascular bed of the cat .
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitoningene-relatedpeptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitoningene–relatedpeptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitoningene-relatedpeptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
Calcitonin/CALCA protein acts as a vasodilator, dilating different blood vessels, including coronary, cerebral, and systemic vessels. Its presence in the central nervous system suggests its potential role as a neurotransmitter or neuromodulator. Calcitonin/CALCA Protein, Human (P. pastoris, His-SUMO) is the recombinant human-derived Calcitonin/CALCA protein, expressed by P. pastoris , with N-SUMO, N-6*His labeled tag. The total length of Calcitonin/CALCA Protein, Human (P. pastoris, His-SUMO) is 37 a.a., with molecular weight of 22 kDa.
Calcitonin/CALCA protein acts as a vasodilator, dilating different blood vessels, including coronary, cerebral, and systemic vessels. Its presence in the central nervous system suggests its potential role as a neurotransmitter or neuromodulator. Calcitonin/CALCA Protein, Human (GST) is the recombinant human-derived Calcitonin/CALCA protein, expressed by E. coli , with N-GST labeled tag. The total length of Calcitonin/CALCA Protein, Human (GST) is 36 a.a., with molecular weight of ~30.6 kDa.
CALCB, known for its vasodilatory effects, induces dilation in various vessels, encompassing the coronary, cerebral, and systemic vasculature. Its notable abundance in the central nervous system suggests a potential role as a neurotransmitter or neuromodulator, underscoring its significance in physiological processes related to vascular regulation and neural signaling. CALCB Protein, Human (HEK293, mFc) is the recombinant human-derived CALCB protein, expressed by HEK293 , with C-mFc labeled tag.
Ubrogepant-d5 (MK-1602-d5) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitoningene-relatedpeptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
Inquiry Online
Your information is safe with us. * Required Fields.
![[Tyr22] Calcitonin Gene Related Peptide, (22-37), rat](http://file.medchemexpress.eu/product_pic/hy-p3689.gif)
